Currently we are examining IL-23 and IL-23R expression levels in a panel of isogenic of parent (sensitive) and resistant NSCLC cell lines generated in our unit (Barr et al., 2013) with a view to conducting combination treatments of Apilimod and cisplatin in future studies. Here, IL23R is linked to non-small cell lung carcinoma.